Ranad Humeidi, PhD is Co-Founder and Chief Science Officer at Omanta, a Y Combinator Summer 2026 company that builds a personalized research lab around a single patient. She works with patients to turn frontier science into personalized treatment strategies.

Ranad earned a PhD in Chemical Biology at Harvard in 3 years, training in the Schreiber and Xavier Labs at the Broad Institute. She began as a UTSA biology major on the MD/PhD track.

At Harvard she identified a druggable ulcerative colitis mechanism that led to a multimillion-dollar collaboration with GSK. She is a chemical biologist focused on bringing frontier biomedical research to patients faster.

Ranad built and directed a multimillion-dollar rare cancer program for one patient, coordinating researchers, physicians, biotechs and drug developers. She has led strategies for 12+ complex patients after standard options were exhausted.

Omanta's researchers worked on the case of GitLab co-founder Sid Sijbrandij, helping bring him into complete remission. The company was featured in Forbes among the Y Combinator Summer 2026 batch.